<DOC>
	<DOCNO>NCT00006029</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy treat patient relapsed refractory Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Relapsed Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose toxicity gemcitabine , vinorelbine , doxorubicin HCl liposome patient relapse refractory Hodgkin 's lymphoma . - Determine complete partial response rate patient treated regimen . OUTLINE : This dose-escalation , multicenter study . Phase I : - Patients receive vinorelbine IV 6-10 minute , gemcitabine IV 30 minute , doxorubicin HCl liposome IV 30-60 minute day 1 8 . Treatment continue every 21 day 2-6 course absence unacceptable toxicity disease progression . Patients respond treatment 2 course may stop protocol therapy undergo peripheral blood stem cell transplantation . Cohorts 3-6 patient receive escalate dos vinorelbine , gemcitabine , doxorubicin HCl liposome maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue receive treatment gemcitabine , vinorelbine , doxorubicin HCl liposome recommend phase II dose . Phase II : - Patients assign 1 2 treatment group . - Group 1 : Patients undergo prior transplantation receive vinorelbine , gemcitabine , doxorubicin HCl liposome phase I . - Group 2 : Patients undergo prior transplantation receive low dos vinorelbine , gemcitabine , doxorubicin HCl liposome group 1 . Patients follow every 6 month 2 year annually 6 year . PROJECTED ACCRUAL : Approximately 3-100 patient ( 3-42 phase I 20-58 phase II [ 29 per group ] ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Hodgkin 's lymphoma recurrent refractory standard chemotherapy Core biopsy acceptable adequate tissue obtain primary diagnosis immunophenotyping Bone marrow biopsy acceptable sole mean diagnosis Measurable disease Tumor mass great 1 cm PATIENT CHARACTERISTICS : Age : Any age Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL unless history Gilbert 's disease AST great 2 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : LVEF least 45 % MUGA ( patient whose lifetime cumulative doxorubicin dose exceeds 400 mg/m^2 ) Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior gemcitabine , vinorelbine , doxorubicin HCl liposome No concurrent chemotherapy Endocrine therapy : No concurrent hormones except nondiseaserelated condition ( e.g. , insulin diabetes ) steroids adrenal failure No concurrent dexamethasone steroidal antiemetic</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
</DOC>